Apollomics Inc.

Animal Exploitation (Testing): Yes Link: https://ir.apollomicsinc.com/news-releases/news-release-details/apollomics-and-launxp-announce-development-and-commercialization/ Short Description: Apollomics is a clinical-stage biopharmaceutical company. Its lead product, vebreltinib (APL-101), was tested for efficacy using preclinical studies that explicitly involved xenograft animal models and patient-derived xenograft models (PDX). This research falls under the category of animal testing for drug development, which is typically required by regulatory bodies like the FDA. Exact Quote from Link: “By targeting c-MET dysregulation, vebreltinib has demonstrated strong tumor inhibitory effect in a variety of preclinical c-MET dysregulated human gastric, hepatic, pancreatic and lung cancer xenograft animal models and patient-derived xenograft models (PDX).”